Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma—A Retrospective Multicenter ADOReg Study
Henner Stege(Johannes Gutenberg University Mainz), Carmen Loquai(Johannes Gutenberg University Mainz), Rudolf Herbst(Helios Klinikum Erfurt), Michael Weichenthal(Christian-Albrechts-Universität zu Kiel), Maria Isabel Fleischer(Johannes Gutenberg University Mainz), Claudia Pföhler(Saarland University), Sebastian Haferkamp(University Hospital Regensburg), Andrea Forschner(University of Tübingen), Katharina C. Kähler(Christian-Albrechts-Universität zu Kiel), Dirk Schadendorf(National Center for Tumor Diseases), Friedegund Meier(National Center for Tumor Diseases), Peter Mohr(Elbe Kliniken Stade-Buxtehude), Stephan Grabbe(Goethe University Frankfurt), Fabian Ziller(Vivantes Klinikum), Elisabeth Livingstone(German Cancer Research Center), Fabienne Bradfisch(Goethe University Frankfurt), Johannes Kleemann(Goethe University Frankfurt), Selma Ugurel(Klinikum Bielefeld), Michael Schultheis(Johannes Gutenberg University Mainz), Lisa Zimmer(The University of Sydney), Maximilian Haist(Johannes Gutenberg University Mainz), Alexander Kreuter(HELIOS St. Elisabeth Klinik Oberhausen), Ulrike Leiter(University of Tübingen), Martin Kaatz(SRH Wald-Klinikum Gera), Dorothée Nashan(Klinikum Dortmund), Patrick Terheyden(University Hospital Schleswig-Holstein), Jens Ulrich, Dirk Debus(Nuremberg Hospital)
Cited by 23
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
|Science|2016|3.1k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k